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ABSTRACT
INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years.
METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects
of treatments for acute gout? What are the effects of treatments to prevent gout in people with prior acute episodes? We searched: Medline,
Embase, The Cochrane Library, and other important databases up to June 2008 (Clinical Evidence reviews are updated periodically, please
check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US
Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found
21 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of
evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the
following interventions: colchicine, corticosteroids, corticotrophin (ACTH), non-steroidal anti-inflammatory drugs (NSAIDs), sulfinpyrazone,
xanthine oxidase inhibitors, advice to lose weight, advice to reduce alcohol intake, advice to reduce dietary intake of purines.
QUESTIONS
What are the effects of treatments for acute gout?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3




Colchicine (oral) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Corticosteroids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Corticotropin (adrenocorticotrophic hormone) . . . . . 5
NSAIDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
PREVENTION OF RECURRENCE
 Unknown effectiveness
Advice to lose weight . . . . . . . . . . . . . . . . . . . . . . . . 7
Advice to reduce alcohol intake . . . . . . . . . . . . . . . . 7
Advice to reduce dietary intake of purines . . . . . . . . 7
Colchicine for preventing recurrence . . . . . . . . . . . . 7
Sulfinpyrazone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Xanthine oxidase inhibitors . . . . . . . . . . . . . . . . . . . . 9
Key points
• Gout is characterised by deposition of urate crystals, causing acute monoarthritis and crystal deposits (tophi) in
the skin.
Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack
within 3 years.
Diagnosis is usually clinical, supported by signs of hyperuricaemia.
Risk factors are those associated with increased serum urate concentrations, including: older age; non-white
ethnicity; obesity; consumption of alcohol, meat, and fish; and use of diuretics.
Hyperuricaemia may be associated with an increased risk of cardiovascular events; we don't know whether it is
an independent risk factor.
• We don't know whether NSAIDs reduce pain and tenderness in an acute attack of gout, although they are commonly
used in clinical practice. They are associated with increased risks of gastrointestinal, and possible cardiovascular,
adverse effects.
Indometacin is widely used to treat acute gout despite the absence of RCT evidence of benefit. Etoricoxib is as
effective as indometacin with reduced risks of gastrointestinal adverse effects.
• Although it has been widely used for many years, we don't know whether oral colchicine improves symptoms in
acute gout. Its use is limited by the high incidence of adverse effects.
• We don't know whether intra-articular, parenteral or oral corticosteroids, or corticotropin (ACTH), improve symptoms
in acute gout.
• We don't know whether colchicine prevents attacks of gout in people with prior episodes, but it may reduce the
risk of an attack in a person starting allopurinol treatment.
We don't know whether advice to lose weight or reduce alcohol or dietary purine intake prevents further attacks
of gout.
We don't know whether allopurinol or febuxostat, orsulfinpyrazone reduce the risk of recurrent attacks compared
with placebo or other treatments.
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DEFINITION Gout is a syndrome caused by deposition of urate crystals. [1]  It typically presents as an acute
monoarthritis of rapid onset. The first metatarsophalangeal joint is the most commonly affected
joint (podagra). Gout also affects other joints; joints in the foot, ankle, knee, wrist, finger, and elbow
are the most frequently affected. Crystal deposits (tophi) may develop around hands, feet, elbows,
and ears. Diagnosis: This is usually made clinically. The American College of Rheumatology
(ACR) criteria for diagnosing gout are as follows: (1) characteristic urate crystals in joint fluid; (2)
a tophus proved to contain urate crystals; or (3) the presence of six or more defined clinical labora-
tory and x ray phenomena (see table 1, p 13 ). [2] We have included studies of people meeting the
ACR criteria, studies in which the diagnosis was made clinically, and studies that used other criteria.
INCIDENCE/
PREVALENCE
Gout is more common in older people and men. [3]  In people aged 65–74 years in the UK, the
prevalence is about 50/1000 in men and about 9/1000 in women. [4] The annual incidence of gout
in people aged over 50 years in the USA is 1.6/1000 in men and 0.3/1000 in women. [5]  One 12-
year longitudinal study of 47,150 male health professionals with no previous history of gout estimated
that annual incidence of gout ranged from 1.0/1000 for those aged 40–44 years to 1.8/1000 for
those aged 55–64 years. [6]  Gout may become more common because of increasing longevity,
obesity, meat and fish consumption, and use of diuretics. [7]  Gout may be more common in some
non-white ethnic groups. [3]  A pooled analysis of two cohort studies of former medical students
found the annual incidence of gout to be 3.1/1000 in black men and 1.8/1000 in white men. [8]  After
correcting for the higher prevalence of hypertension among black men, which is a risk factor for
gout, the relative risk of gout in black men compared with white men was 1.30 (95% CI 0.77 to
2.19). A cross-sectional survey of 657 people aged 15 years and over in New Zealand found a
higher prevalence of gout in Maoris than in people of a European background (6.4% in Maoris v
2.9% in people with European background; age-adjusted RR 3.2, 95% CI 1.6 to 6.6). [9]
AETIOLOGY/
RISK FACTORS
Urate crystals form when serum urate concentration exceeds 0.42 mmol/L. [10]  Serum urate con-
centration is the principal risk factor for a first attack of gout, [11]  although 40% of people have
normal serum urate concentration during an attack of gout. [10] [12] [13] [14]  A cohort study of 2046
men followed up for about 15 years found that the annual incidence was about 0.4% in men with
a urate concentration of 0.42–0.47 mmol/L, rising to 4.3% when serum urate concentration was
0.45–0.59 mmol/L. [15]  One 5-year longitudinal study of 223 asymptomatic men with hyperuricaemia
estimated the 5-year cumulative incidence of gout to be 10.8% for those with baseline serum urate
of 0.42–0.47 mmol/L, 27.7% for baseline urate of 0.48–0.53 mmol/L, and 61.1% for baseline urate
levels of 0.54 mmol/L or more. [11] The study found that a 0.6 mmol/L difference in baseline serum
urate increased the odds of an attack of gout by a factor of 1.8 (OR adjusted for other risk factors
for gout: 1.84, 95% CI 1.24 to 2.72). One 12-year longitudinal study (47,150 male health profes-
sionals with no history of gout) estimated that the relative risks of gout associated with one addi-
tional daily serving of various foods (weekly for seafood) were as follows: meat 1.21 (95% CI 1.04
to 1.41), seafood (fish, lobster, and shellfish) 1.07 (95% CI 1.01 to 1.12), purine-rich vegetables
0.97 (95% CI 0.79 to 1.19), low-fat dairy products 0.79 (95% CI 0.71 to 0.87), and high-fat dairy
products 0.99 (95% CI 0.89 to 1.10). [6] [16]  Alcohol consumption of greater than 14.9 g daily sig-
nificantly increased the risk of gout compared with no alcohol consumption (RR for 15.0–29.9 g/day:
1.49, 95% CI 1.14 to 1.94; RR for 30.0–49.9 g/day: 1.96, 95% CI 1.48 to 2.60; RR for at least
50 g/day: 2.53, 95% CI 1.73 to 3.70). [16] The longitudinal study also estimated the relative risk of
gout associated with an additional serving of beer (355 mL, 12.8 g alcohol), wine (118 mL, 11.0 g
alcohol), and spirits (44 mL, 14.0 g alcohol). It found that an extra daily serving of beer or spirits
was significantly associated with gout, but an extra daily serving of wine was not (RR for 355 mL/day
beer: 1.49, 95% CI 1.32 to 1.70; RR for 44 mL/day spirits: 1.15, 95% CI 1.04 to 1.28; RR for
118 mL/day wine: 1.04, 95% CI 0.88 to 1.22). Other suggested risk factors for gout include obesity,
insulin resistance, dyslipidaemia, hypertension, dietary fructose intake and cardiovascular disorders.
[17] [18] [19]
PROGNOSIS We found few reliable data about prognosis or complications of gout. One study found that 3/11
(27%) people with untreated gout of the first metatarsophalangeal joint had spontaneous resolution
after 7 days. [20]  A case series of 614 people with gout who had not received treatment to reduce
urate levels, and who could recall the interval between first and second attacks, reported recurrence
rates of 62% after 1 year, 78% after 2 years, and 84% after 3 years. [21]  An analysis of two
prospective cohort studies of 371 black and 1181 white male former medical students followed up
for about 30 years found no significant difference in risk of CHD in men who had developed gout
compared with men who had not (RR 0.85, 95% CI 0.40 to 1.81). [22]
AIMS OF
INTERVENTION
For treating gout: to reduce the severity and duration of pain and loss of function, with minimal
adverse effects of treatment. For preventing recurrence: to reduce the frequency and severity
of recurrent attacks, and minimise the adverse effects of interventions.




OUTCOMES For treating gout: severity of symptoms (pain scores, proportion of people with improved symp-
toms), adverse effects of treatment. For preventing recurrence (over 6 months): number of re-
current episodes a year, severity of recurrent episodes a year, adverse effects of treatment.
METHODS Clinical Evidence search and appraisal June 2008. The following databases were used to identify
studies for this systematic review: Medline 1966 to May 2008, Embase 1980 to May 2008, and
The Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled
Clinical Trials 2008, Issue 2. Additional searches were carried out using these websites: NHS
Centre for Reviews and Dissemination (CRD) — for Database of Abstracts of Reviews of Effects
(DARE) and Health Technology Assessment (HTA), Turning Research into Practice (TRIP), and
NICE. We also searched for retractions of studies included in the review. Abstracts of the studies
retrieved from the initial search were assessed by an information specialist. Selected studies were
then sent to the author for additional assessment, using pre-determined criteria to identify relevant
studies. Study design criteria for inclusion in this review were: published systematic reviews and
RCTs in any language, at least single blinded and containing more than 20 people of whom more
than 80% were followed up. For question 1 on treatment of acute gout there was no minimum
length of follow-up required to include studies. For question 2 on prevention of recurrent gout the
minimum length of follow-up is 6 months or longer, except for xanthine oxidase inhibitors plus
prophylactic drugs where the minimum length of follow-up is 3 months. We excluded all studies
described as “open”, “open label”, or not blinded unless blinding was impossible. In addition, we
use a regular surveillance protocol to capture harms alerts from organisations such as the FDA
and the UK Medicines and Healthcare products Regulatory Agency (MHRA), which are added to
the reviews as required. To aid readability of the numerical data in our reviews, we round percent-
ages to the nearest whole number. Readers should be aware of this when relating percentages to
summary statistics such as RRs and ORs. We have performed a GRADE evaluation of the quality
of evidence for interventions included in this review (see table, p 15 ).
QUESTION What are the effects of treatments for acute gout?
OPTION COLCHICINE (ORAL) FOR TREATING ACUTE GOUT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Symptom severity
Compared with placebo Colchicine may be more effective at reducing pain at 48 hours in people with gout (low-
quality evidence).
Note
The high incidence of adverse effects in people taking colchicine precludes its use as a routine treatment. We found
no clinically important results about the effects of colchicine compared with NSAIDs or corticosteroids in people with
gout.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: Colchicine versus placebo:
We found one systematic review (search date 2006) [23]  which found one RCT. [24] The RCT was
small (43 hospital inpatients with acute gout confirmed by synovial fluid examination, aged 55–91
years, 40/43 [93%] men), and compared colchicine (1 mg followed by 0.5 mg every 2 hours as
tolerated or until complete response) versus placebo. [24]  It found that colchicine significantly reduced
pain compared with placebo after 48 hours (pain assessed on a 10 cm visual analogue scale;
proportion with at least 50% improvement in pain: 16/22 [73%] with colchicine v 8/22 [36%] with
placebo; RR 2.00, 95% CI 1.09 to 3.68; P less than 0.05).
Colchicine versus NSAIDs:
We found one systematic review (search date 2006), which found no RCTs. [23] We found no
subsequent RCTs.
Colchicine versus corticosteroids:
We found one systematic review (search date 2006), which found no RCTs. [23] We found no
subsequent RCTs.
Harms: Colchicine versus placebo:
The RCT found that all people taking colchicine experienced diarrhoea, vomiting, or both, within
about 24 hours; 5/21 (24%) people taking placebo developed nausea (significance assessment
not performed). [24] The 50% improvement in pain occurred before diarrhoea and vomiting in 9/22
(40%) people, after the onset of diarrhoea and vomiting in 12/22 (55%) people, and at the same
time in 1/22 (5%) people.





We found no RCTs.
Colchicine versus corticosteroids:
We found no RCTs.
Comment: Clinical guide:
Colchicine has been used since antiquity to treat gout. A large number of observational studies
support its use. Although it may be efficacious, narrow benefit-to-toxicity ratio limits its use in people
with gout. [25]  Colchicine may be useful in people for whom NSAIDs and corticosteroids are con-
traindicated. A dose of 0.5 mg three times daily may have fewer adverse events than the higher
doses commonly used. [26]
OPTION CORTICOSTEROIDS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Symptom severity
Compared with NSAIDS We don't know whether corticosteroids are more effective at reducing pain in people with
acute arthritis suggestive of gout, but they are associated with fewer adverse effects (low-quality evidence).
Compared with corticotropin We don't know whether corticosteroids are more effective at reducing symptoms in
people with acute gout (low-quality evidence).
Note
We found no clinically important results about the effects of intra-articular, parenteral, or oral corticosteroids compared
with no active treatment, NSAIDs, or colchicine in people with gout.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: Corticosteroids versus placebo:
We found one systematic review (search date 2007), which identified no RCTs. [27] We found no
subsequent RCTs.
Corticosteroids versus NSAIDs:
We found one systematic review (search date 2007), [27]  which found one RCT. [28] We found no
subsequent RCTs.The RCT (90 people with an acute arthritis suggestive of gout, 74 males, mean
age 65 years) compared indometacin with prednisolone. People in the indometacin group were
given intramuscular diclofenac initially, and people in both groups received paracetamol. The RCT
found no significant difference in the mean rate of decrease in pain score over the first 2 hours
between the two groups (pain assessed on a 100 mm visual analogue scale; 6.4 mm/hour in the
indometacin group v 9.5 mm/hour in the prednisolone group, mean difference in pain, 3.2 mm/hour;
95% CI –0.78 mm/hour to +7.14 mm/hour; P = 0.12), but found that prednisolone significantly de-
creased mean pain scores during follow-up at days 1 to14 (mean rate of pain decrease; 0.3 mm/day
in the indometacin group v 0.7 mm/day in the prednisolone group, mean difference in pain,
0.5 mm/day; 95% CI 0.03 mm/day to 0.89 mm/day; P = 0.04). After two weeks there was no signif-
icant difference in improvement between the two groups. [28]
Corticosteroids versus colchicine:
We found one systematic review (search date 2007), which found no RCTs. [27] We found no
subsequent RCTs.
Corticosteroids versus corticotropin:
See benefits of corticotropin, p 5 .
Harms: Potential harms of oral corticosteroids are covered elsewhere in Clinical Evidence (see reviews on
rheumatoid arthritis and asthma).
Corticosteroids versus placebo:
We found no RCTs.
Corticosteroids versus NSAIDs:
The RCT found indometacin significantly increased total adverse effects, epigastric pain, and
gastrointestinal haemorrhage compared with prednisolone (total adverse effects: 12/44 [27%] with
prednisolone v 29/46 [63%] with indometacin; P = 0.0007; epigastric pain: 0/44 [0%] with pred-
nisolone v 14/30 [30%] with indometacin; P less than 0.0001; gastrointestinal haemorrhage: 0/44
[0%] with prednisolone v 5/46 [11%] with indometacin; P less than 0.05).The RCT found indometacin
significantly increased hospital admission rates due to serious adverse effects (0/44 [0%] with
prednisolone v 7/46 [15%] with indometacin; P less than 0.007). [28]





We found no RCTs.
Corticosteroids versus corticotropin:
See harms of corticotropin, p 5 .
Comment: Clinical guide:
Both high-dose oral NSAIDs and colchicine have a high incidence of adverse events. Adverse
events from occasional short courses of oral corticosteroids are uncommon. One RCT comparing
indometacin and prednisolone found them to have similar effectiveness, but significantly more
people in the indometacin group developed serious adverse effects. Oral corticosteroids may be
preferable to either NSAIDs or colchicine for the occasional treatment of acute gout. [26]
OPTION CORTICOTROPIN (ADRENOCORTICOTROPHIC HORMONE). . . . . . . . . . . . . . . . . . . . . . . . . .
Symptom severity
Compared with corticosteroids Corticotropin and corticosteroids may be equally effective at reducing symptoms in
people with acute gout (low-quality evidence).
Note
We found no clinically important results about the effects of corticotropin compared with no active treatment or
NSAIDs.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: Corticotropin (adrenocorticotrophic hormone [ACTH]) versus placebo:
We found one systematic review (search date 2007), which found no RCTs. [27] We found no
subsequent RCTs.
Corticotropin versus NSAIDs:
We found one systematic review (search date 2007), which found no RCTs. [27] We found no
subsequent RCTs.
Corticotropin versus corticosteroids:
We found one systematic review (search date 2007), which found one RCT. [27] The RCT (31
males mean age 64 years, mean number affected joints 2.6) found similar mean time to complete
resolution of symptoms with both treatments (7.9 days with corticotropin v 7.6 days with triamci-
nolone; P = 0.89).
Harms: Corticotropin versus placebo:
We found no RCTs.
Corticotropin versus NSAIDs:
We found no RCTs.
Corticotropin versus corticosteroids:
We found one systematic review, which found one RCT that did not report on harms. [27]
Comment: Clinical guide:
Some observational data suggest that corticotropin may be worth considering for people who
cannot tolerate other treatments. [29]
OPTION NSAIDS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Symptom severity
Compared with placebo NSAIDs (tenoxicam) may be more effective at reducing pain at 1 day, but may be no more
effective at reducing pain at 4 days, in people with acute gout (very low-quality evidence).
Compared with each other No one NSAID has been shown to be more effective than the others at reducing pain in
people with acute gout (moderate-quality evidence).
Adverse effects
The adverse effects of different NSAIDs/COX-2 inhibitors include gastrointestinal ulceration and haemorrhage, and
increased cardiovascular risk.
Note




We found no direct information about whether other NSAIDs are better than no active treatment, corticosteroids, or
oral colchicine in people with gout.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: NSAIDs versus placebo:
We found one systematic review (search date 2005, [30]  1 RCT [31] ). The RCT (30 people aged
21–70 years with gout of the knee, ankle, wrist, big toe, or elbow) compared tenoxicam (40 mg
once daily) versus placebo. [31] Tenoxicam significantly increased the proportion of people showing
at least a 50% reduction in pain and tenderness after 1 day compared with placebo (assessed on
a 4-point scale: “disappeared”, “improved by at least 50%”, “unchanged or improved by less than
50%”, or “increased”; AR for pain “improved by at least 50%”: 10/15 [67%] with tenoxicam v 4/15
[26%] with placebo; P less than 0.05; AR for tenderness “improved by at least 50%”: 6/15 [40%]
with tenoxicam v 1/15 [7%] with placebo; P less than 0.05; AR for pain on mobilisation “improved
at least 50%”: 4/15 [27%] with tenoxicam v 1/15 [7%] with placebo; P less than 0.05). However, it
found no significant difference between tenoxicam and placebo in physician-rated efficacy after 4
days (“good or excellent”: 7/15 [47%] with tenoxicam v 4/15 [27%] with placebo; P value not report-
ed).
NSAIDs versus each other:
We found one systematic review (search date 2005), which identified nine RCTs comparing different
NSAIDs versus each other. [30] Two of the high-quality RCTs identified in the review were designed
as equivalence studies comparing indometacin 50 mg three times daily versus etoricoxib 120 mg
daily. These RCTs found indometacin and etoricoxib to be equally effective (see table 2, p 14 ).
[32] [33]
 Four of the remaining seven RCTs identified in the systematic review satisfied our inclusion
criteria.These RCTs failed to show a significant difference in the effect of different NSAIDs on pain
(see table 2, p 14 ). [34] [35] [36] [37]  However, they may have lacked power to show differences.
NSAIDs versus corticosteroids:
See corticosteroids, p 4 .
NSAIDs versus oral colchicine:
See colchicine (oral) for treating acute gout, p 3 .
Harms: The harms of NSAIDs/COX-2 inhibitors are considered in detail elsewhere in Clinical Evidence
and include gastrointestinal ulceration and haemorrhage, and increased cardiovascular risk (see
review on NSAIDs).
NSAIDs versus each other:
See table 2, p 14  for harms.
NSAIDs versus corticosteroids:
See harms of corticosteroids, p 4 .
NSAIDs versus oral colchicine:
See harms of colchicine (oral) for treating acute gout, p 3 .
Comment: NSAIDs versus placebo:
The RCT comparing tenoxicam versus placebo conducted multiple significance tests, and no ad-
justment was reported for this. [31]
NSAIDs versus each other:
Phenylbutazone and indometacin were established as treatments for gout based on uncontrolled
studies. Only the comparisons between etoricoxib and indometacin were powered to show equiv-
alence in efficacy between the two compounds tested. [32] [33] We found six RCTs that compared
phenylbutazone versus other NSAIDs.These were not considered further because phenylbutazone
for gout has been restricted in many countries because it can cause aplastic anaemia and other
serious adverse effects.We found one RCT (93 people) comparing indometacin and azapropazone.
[38] We have not considered this further because use of azapropazone has been restricted because
of a high incidence of gastrointestinal, renal, and hepatic adverse events. [39] We found one RCT
(62 people) comparing meloxicam versus diclofenac versus rofecoxib. [40] We have not considered
this study further because rofecoxib has been withdrawn worldwide because of cardiovascular
adverse effects. The RCT was not designed to compare meloxicam versus diclofenac directly. We
found one RCT (235 people) comparing lumaricoxib with indometacin. [41] This non-inferiority
study found lumaricoxib to be as effective as indometacin at relieving pain.We have not considered
this study further as lumaricoxib has since been withdrawn worldwide because of hepatic adverse
effects.





Although there is little RCT evidence to support their use, traditional NSAIDs, specifically in-
dometacin, are commonly used to treat gout. [42] The choice of NSAID probably depends on doctor
or patient preference. Adverse effects of NSAIDs, including COX-2 inhibitors, often do not manifest
early in treatment. However, it is usual to prescribe proton pump inhibitors to reduce the incidence
of gastrointestinal bleeding as high doses of NSAIDS are used. [43]
QUESTION What are the effects of treatments to prevent gout in people with prior acute episodes?
OPTION ADVICE TO LOSE WEIGHT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
We found no clinically important results about the effects of advice to lose weight on the prevention of attacks
of gout in people with prior episodes.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: We found one systematic review (search date 2005), which identified no RCTs. [30] We found no
subsequent RCTs.
Harms: We found no RCTs.
Comment: None.
OPTION ADVICE TO REDUCE ALCOHOL INTAKE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
We found no clinically important results about the effects of advice to reduce alcohol intake on preventing
attacks of gout in people with prior episodes.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Harms: We found no RCTs.
Comment: A large 12-year longitudinal study (47,150 male health professionals with no history of gout) found
that increased intake of beer or spirits was associated with a significantly increased incidence of
gout. [16]  However it found no significant increase in incidence of gout with increased intake of wine
(see aetiology).
OPTION ADVICE TO REDUCE DIETARY INTAKE OF PURINES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
We found no clinically important results about the effects of advice to reduce dietary intake of purines on
preventing attacks of gout in people with prior episodes.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Harms: We found no RCTs.
Comment: A large longitudinal study (47,150 male health professionals with no history of gout) found that in-
creased intake of meat or seafood was associated with a significantly increased incidence of gout.
[6]
 However, increased intake of purine-rich vegetables did not significantly affect the incidence of
gout. It also found that an increased intake of low-fat dairy produce was associated with a signifi-
cantly reduced incidence of gout (see aetiology).
OPTION COLCHICINE FOR PREVENTING RECURRENCE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recurrence of gout
Colchicine compared with placebo in people starting allopurinol Colchicine may be more effective at reducing the
risk of recurrent attacks of gout at 6 months in people starting allopurinol for recurrent gout (low-quality evidence).
Note




We found no clinically important results about the effects of colchicine compared with no active treatment, xanthine
oxidase inhibitors, sulfinpyrazone, or advice to lose weight, to reduce alcohol, or to reduce dietary purines.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: Colchicine versus placebo:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Colchicine versus advice to lose weight:
See advice to lose weight, p 7 .
Colchicine versus advice to reduce alcohol:
See advice to reduce alcohol intake, p 7 .
Colchicine versus advice to reduce dietary intake of purines:
See advice to reduce dietary intake of purines, p 7 .
Colchicine versus xanthine oxidase inhibitors:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Colchicine versus sulfinpyrazone:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Colchicine plus xanthine oxidase inhibitors versus xanthine oxidase inhibitors alone:
See benefits of xanthine oxidase inhibitors, p 9 .
Harms: Colchicine versus placebo:
We found no RCTs.
Colchicine versus advice to lose weight:
See advice to lose weight, p 7 .
Colchicine versus advice to reduce alcohol:
See advice to reduce alcohol intake, p 7 .
Colchicine versus advice to reduce dietary intake of purines:
See advice to reduce dietary intake of purines, p 7 .
Colchicine versus xanthine oxidase inhibitors:
We found no RCTs.
Colchicine versus sulfinpyrazone:
We found no RCTs.
Colchicine plus xanthine oxidase inhibitors versus xanthine oxidase inhibitors alone:
See harms of xanthine oxidase inhibitors, p 9 .
Comment: Colchicine plus xanthine oxidase inhibitors versus xanthine oxidase inhibitors alone:
See comment on xanthine oxidase inhibitors, p 9 .
Clinical guide:
Colchicine, which has been used since antiquity, may be worth considering for the prevention of
gout for people who cannot tolerate allopurinol.
OPTION SULFINPYRAZONE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recurrence of gout
Sulfinpyrazone compared with placebo Sulfinpyrazone may be no more effective at preventing recurrence of gout
in people taking colchicine (low-quality evidence).
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: Sulfinpyrazone versus placebo:
We found one systematic review (search date 2005), which found one RCT, reported as a conference
abstract only. [30]  It found similar numbers of gout attacks between colchicine plus placebo and




colchicine plus sulfinpyrazone (29 attacks in 170 months of follow-up with colchicine plus placebo
v 32 attacks in 173 months of follow-up with colchicine plus sulfinpyrazone; statistical assessment
not peformed).
Sufinpyrazone versus xanthine oxidase inhibitors:
See xanthine oxidase inhibitors, p 9 .
Harms: The systematic review did not report on harms. [30]
Comment: The RCT identified in by the review was reported as a conference abstract only. [30]
OPTION XANTHINE OXIDASE INHIBITORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recurrence of gout
Xanthine oxidase inhibitors compared with each other Allopurinol and febuxostat are equally effective at preventing
recurrence of gout at 9–52 weeks, but higher-dose febuxostat may increase the risk of recurrence in the first 8 weeks
of treatment in people also taking naproxen or colchicine (moderate-quality evidence).
Xanthine oxidase inhibitors alone compared with xanthine oxidase inhibitors plus prophylactic drugs Initiating treatment
with allopurinol alone may be less effective than initiating treatment with allopurinol during colchicine prophylaxis at
reducing the risk of recurrent attacks of gout at 6 months (low-quality evidence).
Note
We found no clinically important results about the effects of xanthine oxidase inhibitors compared with no active
treatment, sulfinpyrazone, colchicine, or lifestyle interventions.
For GRADE evaluation of interventions for gout, see table, p 15 .
Benefits: Xanthine oxidase inhibitors versus placebo:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Xanthine oxidase inhibitors versus sulfinpyrazone:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Xanthine oxidase inhibitors versus colchicine:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Xanthine oxidase inhibitors versus lifestyle interventions:
We found one systematic review (search date 2005), which found no RCTs. [30] We found no
subsequent RCTs.
Xanthine oxidase inhibitors versus each other:
We found one systematic review (search date 2005), which found no RCTs. [30] We found one
subsequent RCT, which compared allopurinol 300 mg daily versus febuxostat 80 mg daily versus
febuxostat 120 mg daily. [44]  All participants also received naproxen 250 mg twice daily or colchicine
0.6 mg daily during the first 8 weeks of treatment, to reduce the increased incidence of gout flares
that can occur when urate lowering medication is initiated. It found that allopurinol and febuxostat
80 mg significantly reduced the proportion of people with at least one recurrent attack of gout in
the first 8 weeks compared with febuxostat 120 mg (760 people with a history of gout, mean age
52 years, 96% male; AR for recurrence of gout: 52/251 [21%] with allopurinol v 55/255 [22%] with
febuxostat 80 mg v 90/250 [36%] with febuxostat 120 mg; P less than 0.001 for both allopurinol
and febuxostat 80 mg v febuxostat 120 mg). However, there was no significant difference between
either dose of febuxostat and allopurinol in recurrent attacks of gout between weeks 9 and 52
(150/234 [64%] with allopurinol v 147/228 [64%] with febuxostat 80 mg v 150/215 [70%] with
febuxostat 120 mg; P = 0.99 for febuxostat 80 mg v allopurinol; P = 0.23 for febuxostat 120 mg v
allopurinol).
Xanthine oxidase inhibitors alone versus xanthine oxidase inhibitors plus prophylactic
drugs:
We found no systematic review. We found one RCT, which compared colchicine 0.6 mg twice
daily versus placebo as prevention for recurrent gout in people starting treatment with allopurinol
for chronic gouty arthritis. [45] Treatment was continued for 3 months after serum urate reached
normal levels. The dose was reduced to once daily in people with renal insufficiency or gastroin-
testinal adverse effects. The RCT found that colchicine significantly reduced the proportion of




people with recurrent gout attacks at 6 months compared with placebo (proportion of people with
at least 1 attack: 7/21 [33%] with colchicine [12 attacks in total] v 17/22 [77%] with placebo [65 at-
tacks in total]; P = 0.008). The authors report that the finding was significant, but the basis of the
statistical analysis was not clear. It found that colchicine significantly reduced the severity of attacks
compared with placebo (median score on visual analogue scale [scale range not reported]: 3.64
with colchicine v 5.08 with placebo; P = 0.018). There was no significant difference in duration of
attacks (6.00 days with colchicine v 5.56 days with placebo; P = 0.566). [45]
Harms: Xanthine oxidase inhibitors versus placebo:
We found no RCTs.
Xanthine oxidase inhibitors versus sulfinpyrazone:
We found no RCTs.
Xanthine oxidase inhibitors versus colchicine:
We found no RCTs.
Xanthine oxidase inhibitors versus lifestyle interventions:
We found no RCTs.
Xanthine oxidase inhibitors versus each other:
The subsequent RCT found that allopurinol significantly increased adverse events compared with
febuxostat 120 mg (215/253 [85%] with allopurinol v 205/256 [80%] with febuxostat 80 mg v 189/251
[75%] with febuxostat 120 mg; P = 0.01 for allopurinol v febuxostat 120 mg; other statistical assess-
ments not reported). [44] There was no significant difference between treatments in adverse events
considered by the investigators to be possibly, probably, or definitely associated with the study
drug (57/253 [23%] with allopurinol v 63/256 [25%] febuxostat 80 mg v 60/251 [24%] with febuxostat
120 mg; differences reported as not significant; P value not reported). There was no significant
difference between treatments in serious adverse events, all considered by the investigators to be
unlikely to be related to study drugs (19/253 [8%] with allopurinol v 11/256 [4%] with febuxostat
80 mg v 21/251 [8%] with febuxostat 120 mg; differences reported as not significant; P value not
reported). Four people died, two in each of the febuxostat groups (0.8% in both groups) and none
in the allopurinol group (P = 0.31).
Xanthine oxidase inhibitors alone versus xanthine oxidase inhibitors plus prophylactic
drugs:
The RCT found that colchicine significantly increased diarrhoea compared with placebo (38% with
colchicine v 5% with placebo; P = 0.009). However, no one withdrew because of diarrhoea, and
all cases resolved when the dose was reduced. [45]
Comment: We found one open RCT comparing colchicine 0.5 mg twice daily versus colchicine 0.5 mg twice
daily plus allopurinol 300 mg once daily. [46] Three people (10%) allocated to the colchicine plus
allopurinol group who did not take allopurinol were included in the colchicine only group for analysis.
In the first year there was no significant difference between treatments in recurrent attacks of gout
(10/33 [30%] with colchicine alone v 5/26 [19%] with colchicine plus allopurinol; difference reported
as not significant; P value not reported). [46] The primary outcome for the RCT comparing allopurinol
versus febuxostat was a serum urate of less than 0.36 mmol/L at each of the last three monthly
visits. [44]  Both doses of febuxostat significantly increased the proportion of people achieving the
primary end point compared with allopurinol (53/251 [21%] with allopurinol v 136/255 [53%] with
febuxostat 80 mg v 154/250 [62%] with febuxostat 120 mg; P less than 0.001 for allopurinol v
febuxostat 80 mg and febuxostat 120 mg).
Clinical guide:
Many experts believe that allopurinol should not normally be started during an attack of gout.There
is some evidence to support the usual practice of co-prescribing prophylactic drugs, such as
colchicine, when starting urate lowering medication. The focus of this review is the prevention of
recurrent gout rather than reducing serum urate. It is not clear how effective xanthine oxidase in-
hibitors are at reducing the incidence of recurrent gout. If urate lowering drugs are used, then the
dose should be titrated upwards to achieve a target urate level of less than 0.36 mmol/L which
prevents crystal formation and promotes their dissolution. Febuxostat seems more effective than
allopurinol at reducing serum urate, but does not result in a reduction in recurrent gout over the
first year of treatment. Febuxostat might be an alternative for people who cannot tolerate allopurinol.
GLOSSARY
Low-quality evidence Further research is very likely to have an important impact on our confidence in the estimate
of effect and is likely to change the estimate.




Moderate-quality evidence Further research is likely to have an important impact on our confidence in the estimate
of effect and may change the estimate.
Very low-quality evidence Any estimate of effect is very uncertain.
SUBSTANTIVE CHANGES
Colchicine (oral) One updated systematic review added, which identified no new RCTs; [23]  categorisation unchanged
(Unknown effectiveness).
Corticosteroids One systematic review [27]  added, which identified one RCT; [28]  benefits data enhanced; categori-
sation unchanged (Unknown effectiveness).
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TABLE 1 American College of Rheumatology criteria for acute gout (people must fulfill at least 6 criteria). [2]
More than 1 attack of acute arthritis1
Maximum inflammation developed within 1 day2
Monoarthritis attack3
Redness observed over joints4
First metatarsophalangeal joint painful or swollen5
Unilateral first metatarsophalangeal joint attack6
Unilateral tarsal joint attack7
Tophus (proved or suspected)8
Hyperuricaemia9
Asymmetric swelling within a joint on x ray film10
Subcortical cysts without erosions on x ray film11
Joint culture negative for organism during attack12




TABLE 2 RCTs comparing NSAIDs versus each other in people with gout (see text, p 5 ).
Adverse eventsResultsOutcomesPopulationComparison
People reporting at least 1 adverse
events: 45/103 (44%) with etoricoxib v
49/86 (57%) with indometacin; P = 0.08
Drug-related adverse events: 17/103
(17%) with etoricoxib v 32/86 (37%)
with indometacin; P = 0.002*
Difference: –0.08, 95% CI –0.29 to +0.13Pain measured on Likert scale over days
2–5: 0 = no pain to 4 = extreme pain;
Equivalence pre-specified as a difference
of no more than ± 0.5
189 people, gout for less
than 48 hours, who had
previously responded to
NSAIDS, 93% male, mean
age 52 years
Indometacin (50 mg 3 times daily) v etori-
coxib (120 mg/day). Equivalence study [24]
Proportion with adverse events: 17/75
(23%) with etoricoxib v 35/75 (47%)
with indometacin; P = 0.003
Difference: +0.11, 95% CI –0.14 to +0.35Pain measured on Likert scale over days
2–5: 0 = no pain to 4 = extreme pain;
Equivalence pre-specified as a difference
of no more than ± 0.5
150 men, gout for less than
24 hours, mean age 49
years
Indometacin (50 mg 3 times daily) v etori-
coxib (120 mg/day). Equivalence study [30]
The study reported no important ad-
verse events
Day 2: 2.6 with etodolac v 2.8 with naproxen;
reported as not significant;
Day 4: 1.8 with etodolac v 2.0 with naproxen;
reported as not significant;
Day 7: 1.4 with etodolac v 1.4 with naproxen;
reported as not significant
Mean pain scores assessed on a scale 0–5
(higher scores indicating worse pain) after
2, 4, and 7 days
61 people, 18–75 yearsEtodolac (300 mg twice daily) v naproxen
(500 mg twice daily) [26]
The study reported no important ad-
verse events
The study reported there was no significant dif-
ference in pain between etodolac and naproxen
after 1, 2, 4, and 7 days; results presented
graphically, no AR or P values reported
Pain assessed on a 5-point rating scale:
1 = no pain to 5 = very severe pain after 1,
2, 4, and 7 days
60 people, 18–75 yearsEtodolac (300 mg twice daily) v naproxen
(500 mg twice daily) [29]
No differences in important adverse
event rates were found
Day 2: 0.9 with indometacin v 1.1 with ketopro-
fen; P value reported as not significant;
Day 5: 0.8 with indometacin v 1.3 with ketopro-
fen; P value reported as not significant;
Day 8: 0.3 with indometacin v 0.4 with ketopro-
fen; P value reported as not significant
Mean pain scores assessed on a 4-point
scale: 0 = no pain to 3 = severe pain after
2, 5, or 8 days
59 people, gout for less than
48 hours, 35–88 years
Indometacin (up to 225 mg for 1 day in di-
vided doses followed by 50 mg 3 times
daily) v ketoprofen (450 mg in divided doses
for 1 day followed by 100 mg 3 times dai-
ly) [31]
No differences in important adverse
event rates were found
11/12 (92%) with indometacin v 11/12 (92%) with
flurbiprofen; P value not reported
Proportion of people with improved pain at
rest after 2 days
29 peopleIndometacin (50 mg 4 times daily for 4 days
followed by 25 mg 4 times daily for 5 days)
v flurbiprofen (100 mg 4 times daily for 1
day followed by 50 mg 4 times daily for 5
days) [32]
*The RCT did not define serious and drug-related adverse events.




TABLE GRADE evaluation of interventions for gout














What are the effects of treatments for acute gout?
Quality point deducted for sparse data. Direct-
ness point deducted for narrow inclusion criteria
Low0–10–14Colchicine v placeboSymptom severity1 (43) [24]
Quality point deducted for sparse data. Consis-
tency point deducted for different results at differ-
ent end points
Low00–1–14Corticosteroids v NSAIDSSymptom severity1 (90) [27]
Quality point deducted for sparse data. Direct-




Symptom severity1 (31) [30]
Quality points deducted for sparse data and
statistical flaws. Consistency point deducted for
conflicting results at different end points. Direct-
ness point deducted for assessing only one drug.
Effect-size point added for RR greater than 2
Very low+1–1–1–24NSAIDs v placeboSymptom severity1 (30) [31]
Directness point deducted for assessment of
only some NSAIDs
Moderate0–1004NSAIDs v each otherSymptom severity6 (548) [24] [30] [26][29] [31] [32]
What are the effects of treatments to prevent gout in people with prior acute episodes?
Quality points deducted for sparse data and in-
complete reporting of results
Low000–24Sulfinpyrazone plus
colchicine v colchicine plus
placebo
Recurrence of gout1 RCT [30]
Consistency point deducted for conflicting results
at different end points and with different doses
Moderate00–104Xanthine oxidase inhibitors
v each other
Recurrence of gout1 (760) [44]
Quality points deducted for sparse data and for
uncertainty about basis of statistical analysis
Low000–24Xanthine oxidase inhibitors
alone v xanthine oxidase in-
hibitors plus prophylactic
drugs
Recurrence of gout1 (43) [45]
Type of evidence: 4 = RCT; 2 = Observational;
Consistency: similarity of results across studies.
Directness: generalisability of population or outcomes.
Effect size: based on relative risk or odds ratio.
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